Multiple co-primary endpoints: Medical and statistical solutions - A report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America

Drug Information Journal

Volumn 41, Issue 1, 2007, Pages 31-46

  Offen, Walter ^a   Chuang Sfein, Christy ^b   Dmitrienko, Alex ^a   Littman, Gary ^c   Maca, Jeff ^d   Meyerson, Laura ^e   Muirhead, Robb ^b   Stryszak, Paul ^f   Boddy, Alex ^g   Chen, Kun ^c   Copley Merriman, Kati ^b   Dere, Willard ^h   Givens, Sam ⁱ   Hall, David ^j   Henry, David ^k   Jackson, Joseph D ^k   Krishen, Alok ^l   Liu, Thomas ^h   Ryder, Steve ^b   Sankoh, A J ^g   Wang, Julia ^c   Yeh, Chyon Hwa ^m   more..

^a ELI LILLY AND COMPANY   (United States)

^b Pfizer Global R and D

^c Wyeth ^*

^d NOVARTIS   (Switzerland)

^e BIOGEN   (United States)

^f Schering Plough   (Germany)

^g Sanofi Aventis

^h AMGEN INC   (United States)

ⁱ Preclinical Development Pathology   (United States)

^j BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^k BRISTOL MYERS SQUIBB   (United States)

^l GLAXOSMITHKLINE   (United Kingdom)

^m PROCTER AND GAMBLE COMPANY   (United States)

more..

Author keywords

Bayesian approach; Mixed Bayesian frequentist approach; Multiple endpoint expert team; Multiplicity adjustment; Restricted null space; Reverse multiplicity

Indexed keywords

ARTICLE; BAYES THEOREM; BIOASSAY; CLINICAL ASSESSMENT; CLINICAL STUDY; CORRELATION ANALYSIS; DRUG INDUSTRY; DRUG RESEARCH; ENDPOINT; PRIORITY JOURNAL; RESEARCH; STATISTICAL CONCEPTS; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; UNITED STATES;

EID: 33846460001     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150704100105     Document Type: Article

References (28)

1. Hsu JC. Multiple Comparisons-Theory and Methods. Chapman and Hall: London, UK; 1996.
2. Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med. 1997;16:2529-2542.
3. ICH E9. Statistical Principles for Clinical Trials. Step 5 guidance document. 2000. Available at: http://www.ich.org. Accessed November 11, 2006.
4. CPMP/EWP/908/99. Points to consider on multiplicity issues in clinical trials (adopted September 2002). Available at: http://www.emea.eu.int/pdfs/ human/ewp/090899en.pdf. Accessed November 11, 2006.
5. Berger RL. Multiparameter hypothesis testing and acceptance sampling. Technometrics. 1982;24:295-300.
6. Laska EM, Meisner MJ. Testing whether the iden-tified treatment is best. Biometrics. 1989;45:1139-1151.
7. Eaton ML, Muirhead RJ. On a multiple endpoints problem. J Stat Plann Infer. In press.
8. Kong L, Kohberger RC, Koch GG. Type I error and power in noninferiority/equivalence trials with correlated multiple endpoints: an example from vaccine development trials. J Biopharm Stat. 2004;14:893-907.
9. ICH E14. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. Step 3 guidance document. 2004. Available at: http://www.ich .org. Accessed November 11, 2006.
10. Leung HM, O'Neill RT. Statistical assessment of combination drugs-a regulatory view, In: Proceedings of the Annual Meeting of the American Statistical Association; August 7 1986; Chicago, IL; Biopharmaceutical Subsection: 33-36.
11. Snapinn SM. Evaluating the efficacy of a combination therapy. Stat Med. 1987;6:657-665.
12. Temple RJ. A regulatory authorities opinion about surrogate endpoints. In: Nimmo WS, Tucker GT, eds. Clinical Measurement in Drug Evaluation. New York, NY: Wiley; 1995:322.
13. De Gruttola VG, Clax P, DeMets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health Workshop. Control Clin Trials. 2001;22:485-502.
14. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics. 1984;40:1079-1087
15. Caro G, Caro J, O'Brien JA, Anton S, Jackson J. Migraine therapy: development and testing of a patient preference questionnaire. Headache. 1998;38:602-607
16. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000;20:765-786.
17. DeMets DL, Califf RM. Lessons learned from recent cardiovascular clinical trials: part I. Circulations. 2002;106:746-751.
18. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
19. Sankoh AJ, D'Agostino RB, Huque MF. Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues. Stat Med. 2003;22:3133-3150.
20. Offen WW, Helterbrand JD. Multiple comparison adjustments when two or more co-primary endpoints must all be statistically significant. In: Proceedings of the Annual Meeting of the American Statistical Association; August 7, 1986; Chicago, IL; Biopharmaceutical Subsection.
21. Patel HI. Comparison of treatments in a combination therapy trial. J Biopharm Stat. 1991;1:171-183.
22. Snapinn SM, Sarkar SK. Assessing the superiority of a combination drug with a specific alternative. J Biopharm Stat. 1996;6:241-251.
23. Chuang-Stein C, Stryszak P, Dmitrienko A, Offen W. Challenge of multiple co-primary endpoints; new approache. Stat Med. In press.
24. Casella G, Berger RL. Statistical Inference. 2nd ed. St. Paul, MN: Brooks/Cole; 2001.
25. Box GEP, Tiao GC. Bayesian Inference in Statistical Analysis. New York: Wiley Classics Library; 1992. [Original work published 1973.]
26. Grieve A, Muirhead RJ. A Bayesian approach to the multiple endpoints problem. Unpublished manuscript.
27. Food and Drug Administration. The Critical Path to New Medical Products. March 2004. Available at: http://www.fda.gov/oc/initiatives/criticalpath/ whitepaper.html. Accessed November 11, 2006.
28. Dmitrienko A, Offen W, Westfall P. Gatekeeping testing strategies in clinical trials. Stat Med. 2003;22:2387-2400.